JP2016517394A5 - - Google Patents

Download PDF

Info

Publication number
JP2016517394A5
JP2016517394A5 JP2015560191A JP2015560191A JP2016517394A5 JP 2016517394 A5 JP2016517394 A5 JP 2016517394A5 JP 2015560191 A JP2015560191 A JP 2015560191A JP 2015560191 A JP2015560191 A JP 2015560191A JP 2016517394 A5 JP2016517394 A5 JP 2016517394A5
Authority
JP
Japan
Prior art keywords
cells
cell composition
hematopoietic cell
body weight
recipient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015560191A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016517394A (ja
JP6305443B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/015394 external-priority patent/WO2014133729A1/en
Publication of JP2016517394A publication Critical patent/JP2016517394A/ja
Publication of JP2016517394A5 publication Critical patent/JP2016517394A5/ja
Application granted granted Critical
Publication of JP6305443B2 publication Critical patent/JP6305443B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015560191A 2013-02-26 2014-02-07 移植片の移植寛容のための組み合わされた臓器及び造血細胞 Active JP6305443B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361769596P 2013-02-26 2013-02-26
US61/769,596 2013-02-26
PCT/US2014/015394 WO2014133729A1 (en) 2013-02-26 2014-02-07 Combined organ and hematopoietic cells for transplantation tolerance of grafts

Publications (3)

Publication Number Publication Date
JP2016517394A JP2016517394A (ja) 2016-06-16
JP2016517394A5 true JP2016517394A5 (enExample) 2017-03-09
JP6305443B2 JP6305443B2 (ja) 2018-04-04

Family

ID=51388802

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015560191A Active JP6305443B2 (ja) 2013-02-26 2014-02-07 移植片の移植寛容のための組み合わされた臓器及び造血細胞

Country Status (9)

Country Link
US (21) US9504717B2 (enExample)
EP (3) EP3804735A1 (enExample)
JP (1) JP6305443B2 (enExample)
KR (2) KR20150132196A (enExample)
CN (2) CN105188755A (enExample)
AU (2) AU2014221330B2 (enExample)
CA (1) CA2902098A1 (enExample)
GB (2) GB2558680B (enExample)
WO (1) WO2014133729A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6305443B2 (ja) 2013-02-26 2018-04-04 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 移植片の移植寛容のための組み合わされた臓器及び造血細胞
KR102164405B1 (ko) * 2013-03-14 2020-10-12 더 존스 홉킨스 유니버시티 나노스케일 인공 항원 제시 세포
US20190000885A1 (en) * 2015-11-30 2019-01-03 The General Hospital Corporation Treatment with angiogenin to enhance hematopoietic reconstitution
WO2019178106A1 (en) * 2018-03-12 2019-09-19 Medeor Therapeutics, Inc. Methods for treating non-cancerous disorders using hematopoietic cells
US10842821B2 (en) * 2018-04-05 2020-11-24 Medeor Therapeutics, Inc. Cellular compositions derived from prior organ donors and methods of manufacture and use thereof
US10881692B2 (en) * 2018-04-05 2021-01-05 Medeor Therapeutics, Inc. Compositions for establishing mixed chimerism and methods of manufacture thereof
WO2020047236A1 (en) * 2018-08-30 2020-03-05 The Regents Of The University Of California Mobilization and collection of peripheral blood hematopoietic stem cells from deceased donors
US11435350B2 (en) 2018-09-18 2022-09-06 Medeor Therapeutics, Inc. Methods of analysis of blood from deceased donors
CA3112320A1 (en) * 2018-09-18 2020-03-26 Medeor Therapeutics, Inc. Cellular compositions derived from deceased donors to promote graft tolerance and manufacture and uses thereof
US11813376B2 (en) 2018-09-18 2023-11-14 Medeor Therapeutics, Inc. Cellular compositions derived from deceased donors to promote graft tolerance and manufacture and uses thereof
US20200086004A1 (en) * 2018-09-18 2020-03-19 Medeor Therapeutics, Inc. Methods of making cellular compositions derived from deceased donors to promote graft tolerance
WO2020121988A1 (ja) * 2018-12-09 2020-06-18 国立大学法人北海道大学 免疫抑制作用又は免疫寛容誘導作用を評価する方法、及び免疫寛容誘導剤
JP7395174B2 (ja) * 2018-12-09 2023-12-11 国立大学法人北海道大学 免疫抑制作用又は免疫寛容誘導作用を評価する方法、及び免疫寛容誘導剤
US11697799B2 (en) 2019-04-15 2023-07-11 Ossium Health, Inc. System and method for extraction and cryopreservation of bone marrow
US20220305057A1 (en) * 2019-06-06 2022-09-29 Medeor Therapeutics, Inc. Methods of making cellular products by post- mortem mobilization and harvesting of hematopoietic cells
JP2023500277A (ja) * 2019-11-05 2023-01-05 イェダ リサーチ アンド デベロップメント カンパニー リミテッド T細胞媒介性自己免疫疾患の治療におけるベト細胞の使用
US20230201256A1 (en) * 2020-05-21 2023-06-29 Medeor Therapeutics, Inc. Calcineurin inhibitor to improve cd3+cell survival to thereby facilitate engraftment of donor cd34+ cells in a recipient
EP4181675A4 (en) 2020-07-18 2024-04-24 Ossium Health, Inc. PERMEATION OF WHOLE VERTEBRATE BODIES WITH A CRYOPRETECTIVE AGENT USING VACUUM-ASSISTED DIFFUSION
JP2023543863A (ja) * 2020-09-30 2023-10-18 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー ドナー造血細胞キメリズム並びに臓器及び組織移植並びに自己免疫寛容
CA3195653A1 (en) * 2020-10-14 2022-04-21 Ossium Health, Inc. Systems and methods for extraction and cryopreservation of bone marrow
WO2022133282A1 (en) * 2020-12-18 2022-06-23 Ossium Health, Inc. Methods of cell therapies
CN112669992B (zh) * 2020-12-30 2024-06-11 中国人民解放军总医院 单倍体造血干细胞移植atg个体化用药量的计算方法
WO2022159824A1 (en) * 2021-01-25 2022-07-28 Ossium Health, Inc. Methods of cell therapies
JP2024511277A (ja) 2021-02-19 2024-03-13 メビオン・メディカル・システムズ・インコーポレーテッド 粒子線治療システムのためのガントリー
CN113813454B (zh) * 2021-08-30 2022-09-09 四川大学华西医院 一种采集器官捐献供体血液的方法
JP2024534926A (ja) * 2021-09-07 2024-09-26 ゼラリオン マルタ リミテッド 寛容性を誘導するための方法及び組成物
US12584107B2 (en) 2022-01-20 2026-03-24 3T Biosciences, Inc. T cell receptor (TCR) compositions and methods for optimizing antigen reactive T-cells
EP4633647A1 (en) * 2022-12-16 2025-10-22 The Regents of the University of California Retro-active (delayed) immunological tolerance induction in patients with pre-existing solid organ transplants
WO2025231133A1 (en) * 2024-04-30 2025-11-06 University Of Kentucky Research Foundation GENERATION OF TOLEROGENIC ORGANS USING NORMOTHERMIC or HYPOTHERMIC PERFUSION PUMP WITH TREG CELL BASED IMMUNOTHERAPY WITH OR WITHOUT STEM CELLS

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69723888T2 (de) 1996-05-09 2004-05-27 The General Hospital Corp., Boston Gemischter Chimerismus und Toleranz
AU1585799A (en) 1997-11-14 1999-06-07 General Hospital Corporation, The Treatment of hematologic disorders
AU748443B2 (en) * 1998-02-04 2002-06-06 General Hospital Corporation, The Costimulatory blockade and mixed chimerism in transplantation
WO2000045842A2 (en) 1999-02-04 2000-08-10 The General Hospital Corporation Methods for human allografting
WO2001078653A2 (en) * 2000-04-14 2001-10-25 Millennium Pharmaceuticals, Inc. Graft rejection inhibition with ccr2 inhibitors
JP2002092615A (ja) 2000-09-20 2002-03-29 Fujitsu Ltd 画像処理装置及び画像形成装置
WO2002040640A2 (en) * 2000-11-14 2002-05-23 The University Of Louisville Research Foundation, Inc. Methods of using cd8+/tcr- facilitating cells (fc) for the engraftment of purified hematopoietic stem cells (hsc)
US20030031652A1 (en) * 2001-04-16 2003-02-13 Bernhard Hering Systems and methods for inducing mixed chimerism
WO2003012060A2 (en) * 2001-08-01 2003-02-13 Jewish Hospital Healthcare Services, Inc. Cellular compositions which facilitate engraftment of hematopoietic stem cells while minimizing the risk of gvhd
US20060127399A1 (en) * 2004-09-13 2006-06-15 Defu Zeng Compositions and methods for inducing chimerism in a subject
US7811815B2 (en) 2004-11-15 2010-10-12 The Board Of Trustees Of The Leland Stanford Junior University Therapeutic uses of allogeneic myeloid progenitor cells
JP2008546647A (ja) * 2005-06-08 2008-12-25 デューク ユニバーシティ 移植のための抗−cd19抗体治療
US8916147B2 (en) 2005-08-24 2014-12-23 Yeda Research and Devolpment Co. Ltd. Universal donor-derived tolerogenic cells for inducing non-syngeneic transplantation tolerance
WO2007033221A2 (en) * 2005-09-13 2007-03-22 The General Hospital Corporation Methods and compositions for inhibition of immune responses
US8632768B2 (en) 2008-05-30 2014-01-21 University Of Louisville Research Foundation, Inc. Human facilitating cells
EP2507630B1 (en) * 2009-12-02 2017-01-25 The Board of Trustees of The Leland Stanford Junior University Biomarkers for determining an allograft tolerant phenotype
US20110137375A1 (en) 2009-12-03 2011-06-09 Mcbride Keith System and method for detection of inversion and eversion of the foot using a multi-chamber insole
CA2823782C (en) * 2011-01-10 2019-05-07 Samuel Strober Enhancement of allogeneic hematopoietic stem cell transplantation
JP2015508101A (ja) * 2012-02-21 2015-03-16 バクスター・インターナショナル・インコーポレイテッドBaxter International Incorp0Rated Cd34+細胞を含む薬学的組成物
JP6305443B2 (ja) 2013-02-26 2018-04-04 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 移植片の移植寛容のための組み合わされた臓器及び造血細胞

Similar Documents

Publication Publication Date Title
JP2016517394A5 (enExample)
WO2010059401A3 (en) Compounds that expand hematopoietic stem cells
JP2009526784A5 (enExample)
JP2009521930A5 (enExample)
EP4269601A3 (en) Modified t cells and methods of making and using the same
AR057582A1 (es) Agentes para suprimir la induccion de linfocitos t citotoxicos
EA202190722A1 (ru) Клинические композиции
Orlando et al. Organ bioengineering, regeneration and repair: where the future of organ transplantation is taking shape
Ekser et al. Current status of pig liver xenotransplantation
WO2012102937A3 (en) Benz imidazole compounds that expand hematopoietic stem cells
Fernandez Improving the outcome of cord blood transplantation: use of mobilized HSC and other cells from third party donors
Issa et al. The potential role for regulatory T-cell therapy in vascularized composite allograft transplantation
Cascalho et al. New technologies for organ replacement and augmentation
Alexander et al. Innovative strategies to increase cardiac donor availability
Gonzalez-Llano et al. Outpatient Haploidentical Peripheral Blood Stem-Cell Transplantation with Post-Transplant Cyclophosphamide in Children and Adolescents
Goussetis et al. Directed sibling donor cord blood banking for children with β-thalassemia major in Greece: usage rate and outcome of transplantation for HLA-matched units
Shakeri et al. Can thymic tissue induce tolerance to kidney allografts?
van Rood et al. Indirect Evidence That Maternal Microchimerism in Cord Blood (CB) Mediates a Graft Versus Leukemia Effect After Transplantation to Unrelated CB Graft Recipients
Morzycka-Michalik et al. Transplantation of kidneys harvested
Hong et al. Feasibility of second hematopoietic stem cell transplantation using reduced-intensity conditioning with fludarabine and melphalan after a failed autologous hematopoietic stem cell transplantation
Baranovski et al. Human α1-Antitrypsin and Temporary T Cell Depletion Synergize to Expand Regulatory T Cells and to Extend Allogeneic Skin Graft Survival.: Abstract# C1588
Ho et al. 121: Mesenchymal stem cells for treatment of steroid-resistant graft-versus-host disease
Lord et al. Sa. 116. Loss of Regulatory T Cell Function Mediated by Antigen Presenting Cells from Surgically Resected Colons from IBD Patients
UA103206C2 (ru) Соединения, которые способствуют росту гемотопоэтических стволовых клеток
TURAN et al. Baskent University, School of Medicine Department of General Surgery Transplantation Unit Ankara, Turkey